Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study

Massimo Berger, Roberto Frairia, Wanda Piacibello, Fiorella Sanavio, Alessandra Palmero, Claudio Venturi, Ymera Pignochino, Laura Berta, Enrico Madon, Massimo Aglietta, Franca Fagioli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective. Cord blood CD34+ cells are more uncommitted than their adult counterparts as they can be more easily maintained and expanded in vitro and transduced with lentiviral vectors. The aim of this study was to evaluate whether pretreatment with high-energy shock waves (HESW) could further enhance the expansion of cord blood progenitors and the transduction efficiency with lentiviral vectors. Methods. Human cord blood CD34+ cells underwent HESW treatment with a wide range of energy and number of shots (from 0.22 mJ/mm2 to 0.43 mJ/mm2 and from 200 to 1500 shots). Cells were then evaluated both for their in vitro expansion ability and in vivo engraftment in primary, secondary, and tertiary NOD/SCID mice. The transduction efficiency with a lentiviral vector (LV) was also evaluated in vitro and in vivo. Results. Cell viability following HESW ranged from 75 to 92%. Pretreatment with HESW significantly improved early progenitor cell expansion after short-term suspension culture. Upon transplantation in primary NOD/SCID mice, the HESW treatment enhanced progenitor cell engraftment (total human CD45 +CD34+ cells were 10% in controls and 14.5% following HESW, human CD45+CD34+CD38- cells were 0.87% in controls and 1.8% following HESW). HESW treatment enhanced the transduction of a GFP+ lentiviral vector (e.g., at day 42 of culture 6.5% GFP + cells in LV-treated cell cultures compared to 11.4% of GFP + cells in HESW-treated cell cultures). The percentage of human GFP+ cell engrafting NOD/SCID mice was similar (34% vs 26.4% in controls); however, the total number of human cells engrafted after HESW was higher (39.6% vs 15%). Conclusion. The pretreatment of CD34+ cells with HESW represents a new method to manipulate the CD34+ population without interfering with their ability to both expand and engraft and it might be considered as a tool for genetic approaches.

Original languageEnglish
Pages (from-to)1371-1387
Number of pages17
JournalExperimental Hematology
Volume33
Issue number11
DOIs
Publication statusPublished - Nov 2005

Fingerprint

High-Energy Shock Waves
Fetal Blood
Blood Cells
Stem Cells
Inbred NOD Mouse
SCID Mice
In Vitro Techniques
Cell Culture Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Berger, M., Frairia, R., Piacibello, W., Sanavio, F., Palmero, A., Venturi, C., ... Fagioli, F. (2005). Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study. Experimental Hematology, 33(11), 1371-1387. https://doi.org/10.1016/j.exphem.2005.08.002

Feasibility of cord blood stem cell manipulation with high-energy shock waves : An in vitro and in vivo study. / Berger, Massimo; Frairia, Roberto; Piacibello, Wanda; Sanavio, Fiorella; Palmero, Alessandra; Venturi, Claudio; Pignochino, Ymera; Berta, Laura; Madon, Enrico; Aglietta, Massimo; Fagioli, Franca.

In: Experimental Hematology, Vol. 33, No. 11, 11.2005, p. 1371-1387.

Research output: Contribution to journalArticle

Berger, M, Frairia, R, Piacibello, W, Sanavio, F, Palmero, A, Venturi, C, Pignochino, Y, Berta, L, Madon, E, Aglietta, M & Fagioli, F 2005, 'Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study', Experimental Hematology, vol. 33, no. 11, pp. 1371-1387. https://doi.org/10.1016/j.exphem.2005.08.002
Berger, Massimo ; Frairia, Roberto ; Piacibello, Wanda ; Sanavio, Fiorella ; Palmero, Alessandra ; Venturi, Claudio ; Pignochino, Ymera ; Berta, Laura ; Madon, Enrico ; Aglietta, Massimo ; Fagioli, Franca. / Feasibility of cord blood stem cell manipulation with high-energy shock waves : An in vitro and in vivo study. In: Experimental Hematology. 2005 ; Vol. 33, No. 11. pp. 1371-1387.
@article{28429ed64c674a7c9a2db4b26d0d7794,
title = "Feasibility of cord blood stem cell manipulation with high-energy shock waves: An in vitro and in vivo study",
abstract = "Objective. Cord blood CD34+ cells are more uncommitted than their adult counterparts as they can be more easily maintained and expanded in vitro and transduced with lentiviral vectors. The aim of this study was to evaluate whether pretreatment with high-energy shock waves (HESW) could further enhance the expansion of cord blood progenitors and the transduction efficiency with lentiviral vectors. Methods. Human cord blood CD34+ cells underwent HESW treatment with a wide range of energy and number of shots (from 0.22 mJ/mm2 to 0.43 mJ/mm2 and from 200 to 1500 shots). Cells were then evaluated both for their in vitro expansion ability and in vivo engraftment in primary, secondary, and tertiary NOD/SCID mice. The transduction efficiency with a lentiviral vector (LV) was also evaluated in vitro and in vivo. Results. Cell viability following HESW ranged from 75 to 92{\%}. Pretreatment with HESW significantly improved early progenitor cell expansion after short-term suspension culture. Upon transplantation in primary NOD/SCID mice, the HESW treatment enhanced progenitor cell engraftment (total human CD45 +CD34+ cells were 10{\%} in controls and 14.5{\%} following HESW, human CD45+CD34+CD38- cells were 0.87{\%} in controls and 1.8{\%} following HESW). HESW treatment enhanced the transduction of a GFP+ lentiviral vector (e.g., at day 42 of culture 6.5{\%} GFP + cells in LV-treated cell cultures compared to 11.4{\%} of GFP + cells in HESW-treated cell cultures). The percentage of human GFP+ cell engrafting NOD/SCID mice was similar (34{\%} vs 26.4{\%} in controls); however, the total number of human cells engrafted after HESW was higher (39.6{\%} vs 15{\%}). Conclusion. The pretreatment of CD34+ cells with HESW represents a new method to manipulate the CD34+ population without interfering with their ability to both expand and engraft and it might be considered as a tool for genetic approaches.",
author = "Massimo Berger and Roberto Frairia and Wanda Piacibello and Fiorella Sanavio and Alessandra Palmero and Claudio Venturi and Ymera Pignochino and Laura Berta and Enrico Madon and Massimo Aglietta and Franca Fagioli",
year = "2005",
month = "11",
doi = "10.1016/j.exphem.2005.08.002",
language = "English",
volume = "33",
pages = "1371--1387",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "11",

}

TY - JOUR

T1 - Feasibility of cord blood stem cell manipulation with high-energy shock waves

T2 - An in vitro and in vivo study

AU - Berger, Massimo

AU - Frairia, Roberto

AU - Piacibello, Wanda

AU - Sanavio, Fiorella

AU - Palmero, Alessandra

AU - Venturi, Claudio

AU - Pignochino, Ymera

AU - Berta, Laura

AU - Madon, Enrico

AU - Aglietta, Massimo

AU - Fagioli, Franca

PY - 2005/11

Y1 - 2005/11

N2 - Objective. Cord blood CD34+ cells are more uncommitted than their adult counterparts as they can be more easily maintained and expanded in vitro and transduced with lentiviral vectors. The aim of this study was to evaluate whether pretreatment with high-energy shock waves (HESW) could further enhance the expansion of cord blood progenitors and the transduction efficiency with lentiviral vectors. Methods. Human cord blood CD34+ cells underwent HESW treatment with a wide range of energy and number of shots (from 0.22 mJ/mm2 to 0.43 mJ/mm2 and from 200 to 1500 shots). Cells were then evaluated both for their in vitro expansion ability and in vivo engraftment in primary, secondary, and tertiary NOD/SCID mice. The transduction efficiency with a lentiviral vector (LV) was also evaluated in vitro and in vivo. Results. Cell viability following HESW ranged from 75 to 92%. Pretreatment with HESW significantly improved early progenitor cell expansion after short-term suspension culture. Upon transplantation in primary NOD/SCID mice, the HESW treatment enhanced progenitor cell engraftment (total human CD45 +CD34+ cells were 10% in controls and 14.5% following HESW, human CD45+CD34+CD38- cells were 0.87% in controls and 1.8% following HESW). HESW treatment enhanced the transduction of a GFP+ lentiviral vector (e.g., at day 42 of culture 6.5% GFP + cells in LV-treated cell cultures compared to 11.4% of GFP + cells in HESW-treated cell cultures). The percentage of human GFP+ cell engrafting NOD/SCID mice was similar (34% vs 26.4% in controls); however, the total number of human cells engrafted after HESW was higher (39.6% vs 15%). Conclusion. The pretreatment of CD34+ cells with HESW represents a new method to manipulate the CD34+ population without interfering with their ability to both expand and engraft and it might be considered as a tool for genetic approaches.

AB - Objective. Cord blood CD34+ cells are more uncommitted than their adult counterparts as they can be more easily maintained and expanded in vitro and transduced with lentiviral vectors. The aim of this study was to evaluate whether pretreatment with high-energy shock waves (HESW) could further enhance the expansion of cord blood progenitors and the transduction efficiency with lentiviral vectors. Methods. Human cord blood CD34+ cells underwent HESW treatment with a wide range of energy and number of shots (from 0.22 mJ/mm2 to 0.43 mJ/mm2 and from 200 to 1500 shots). Cells were then evaluated both for their in vitro expansion ability and in vivo engraftment in primary, secondary, and tertiary NOD/SCID mice. The transduction efficiency with a lentiviral vector (LV) was also evaluated in vitro and in vivo. Results. Cell viability following HESW ranged from 75 to 92%. Pretreatment with HESW significantly improved early progenitor cell expansion after short-term suspension culture. Upon transplantation in primary NOD/SCID mice, the HESW treatment enhanced progenitor cell engraftment (total human CD45 +CD34+ cells were 10% in controls and 14.5% following HESW, human CD45+CD34+CD38- cells were 0.87% in controls and 1.8% following HESW). HESW treatment enhanced the transduction of a GFP+ lentiviral vector (e.g., at day 42 of culture 6.5% GFP + cells in LV-treated cell cultures compared to 11.4% of GFP + cells in HESW-treated cell cultures). The percentage of human GFP+ cell engrafting NOD/SCID mice was similar (34% vs 26.4% in controls); however, the total number of human cells engrafted after HESW was higher (39.6% vs 15%). Conclusion. The pretreatment of CD34+ cells with HESW represents a new method to manipulate the CD34+ population without interfering with their ability to both expand and engraft and it might be considered as a tool for genetic approaches.

UR - http://www.scopus.com/inward/record.url?scp=27544464281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544464281&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2005.08.002

DO - 10.1016/j.exphem.2005.08.002

M3 - Article

C2 - 16263422

AN - SCOPUS:27544464281

VL - 33

SP - 1371

EP - 1387

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 11

ER -